Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein (a) in patients with hyperlipidaemia

W Bartens1, D J Rader, G Talley

  • 1Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

European Journal of Clinical Investigation
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A catalog of associations between rare coding variants and COVID-19 outcomes.

medRxiv : the preprint server for health sciences·2021
Same author

Genome-wide analysis in 756,646 individuals provides first genetic evidence that <i>ACE2</i> expression influences COVID-19 risk and yields genetic risk scores predictive of severe disease.

medRxiv : the preprint server for health sciences·2021
Same author

Development and feasibility of quantitative dynamic cardiac imaging for mice using μSPECT.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2020
Same author

Deletion of murine Arv1 results in a lean phenotype with increased energy expenditure.

Nutrition & diabetes·2015
Same author

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Atherosclerosis·2015
Same author

High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.

Clinical pharmacology and therapeutics·2014

Patients with hyperlipidaemia, particularly those with high cholesterol, show elevated lipoprotein (a) [Lp(a)] levels. However, elevated triglycerides are associated with normal to low Lp(a) concentrations, suggesting a complex relationship.

Area of Science:

  • Cardiovascular Science
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • Lipoprotein (a) [Lp(a)] is an atherogenic lipoprotein, structurally similar to LDL but metabolically distinct.
  • Factors influencing plasma Lp(a) concentrations are not well understood.
  • Hyperlipidaemia is a known risk factor for cardiovascular disease.

Purpose of the Study:

  • To investigate the hypothesis that patients with hyperlipidaemia have elevated Lp(a) levels.
  • To determine the phenotype, concentration, and distribution of Lp(a) in hyperlipidaemic patients compared to controls.

Main Methods:

  • A comparative study involving 107 hyperlipidaemic patients and 128 control subjects.
  • Measurement of plasma Lp(a) concentrations.
  • Subgroup analysis based on elevated cholesterol (> 200 mg/dL) and triglyceride (> 200 mg/dL) levels.

Related Experiment Videos

Main Results:

  • Significantly increased Lp(a) concentrations in hyperlipidaemic patients (mean 34 ± 4 mg/dL) compared to controls (mean 20 ± 3 mg/dL).
  • Lp(a) concentrations were 2.3-fold higher in patients with high cholesterol (mean 45 ± 5 mg/dL) versus high triglycerides (mean 20 ± 4 mg/dL).
  • A negative correlation between triglyceride and Lp(a) levels was observed in patients with very high triglyceride levels (> 300-400 mg/dL).

Conclusions:

  • Plasma Lp(a) concentrations are elevated in hyperlipidaemia, particularly in patients with high cholesterol.
  • Elevated triglycerides in hyperlipidaemic patients are associated with normal to low Lp(a) levels.
  • These findings highlight the differential impact of cholesterol and triglyceride levels on Lp(a) concentrations in hyperlipidaemia.